Board of Directors

William Wang Ching-Dong, Chief Executive Officer and Chairman of the Board, has served as Chief Executive Officer and the sole director of SL BIO Ltd. since March 2024. Mr. Wang is an accomplished executive with over a decade of leadership experience in the management and biotechnology sectors. Mr. Wang has served as Chief Executive Officer and Chairman of, SL Link Co., Ltd., since January 2011, SL Bio Co., Ltd, the subsidiary of SL Bio, since July 2022. Mr. Wang has also served as Chief Executive Officer and Chairman of Wenqing Investment Co., Ltd., an investment company, since 2012, and UTRUST Co., Ltd., a trading company, since 2013. In these roles he has been responsible for strategic direction, corporate governance, and operational oversight. Mr. Wang’s expertise spans corporate management, investment, and business development, with a focus on driving growth and innovation in the life sciences and technology industries. Mr. Wang graduated from Chung Yuan Christian University with a degree in electrical engineering. We believe Mr. Wang is qualified to serve on our board of directors due to his extensive experience in corporate leadership and his proven track record in managing and growing companies in the biotechnology and investment sectors.

Ray Leung, Chief Financial Officer, has served as Chief Financial Officer (“CFO”) of SL BIO Ltd. since December 2025. Mr. Leung is a dedicated professional with experience across areas of auditing, taxation and accounting related industry. From April 2007 to June 2017, Mr. Leung is the audit manager at East Asia Sentinel Limited CPA (BKR International), where he was responsible for the audit engagement management of a client portfolio including MNCs, private equity fund (in accordance with US GAAP and IFRS), assets management (regulated activities registered under Securities and Futures Ordinance) and listed corporations on the Main Board of Hong Kong Stock Exchange; and planned, directed, and completed audit projects including general controls, compliance and other specialized audits. From June 2017 till December 2025, he was the senior manager at ST Lo & Co., CPA and SSC Corporate Services Limited, where he managed the engagement team to provide Pre-IPO services to clients, established and maintained investor relations matters, and other corporate finance advisory services. During the same period, he served as the company secretary to FAR International Holdings (HK:2516). Mr. Leung is a member of Hong Kong Institute of Certified Public Accountants, a Fellow Chartered Certified Accountant (FCCA), and a Certified Environmental Social and Governance Analyst (CESGA). Mr. Leung received the Bachelor of Arts (with Honours) in Accountancy degree from the Hong Kong Polytechnic University in 2003.

Ethan Shen, Ph.D., Chief Technology Officer, has served as Chief Technology Officer since January 2025. Dr. Shen has deep expertise in translational medicine, new drug development, medical-grade health product development, and financial management. From 2001 to 2008, Dr. Shen served as the Key Account Manager at Novartis, where he managed projects and oversaw new drug submissions. His expertise spans R&D, innovation and entrepreneurship, financial management, as well as genetics and cellular technologies. Dr. Shen is currently director of EG BioMed and Shen Capital Co., Ltd. Dr. Shen graduated from Taipei Medical University with a degree in Pharmacy and holds a pharmacist license. Dr. Shen also holds a master’s degree in finance from Baruch College, CUNY, and executive MBA degrees from National Taiwan University and Fudan University. Dr. Shen obtained a Ph.D. in Translational Medicine from Academia Sinica and Taipei Medical University.

Mingche Liu, M.D., Ph.D., Independent Director Nominee, will serve as a Director of PubCo following the consummation of the Business Combination. Dr. Liu has served as the vice superintendent at Taipei Cancer Center, Taipei Medical University from August 2025. He has also served as the professor at School of Dental Technology, Taipei Medical University from February 2024 and the director of the Division of Urology, Taipei Medical University Hospital from August 2021. From February 2022 to July 2024, Dr. Liu served as the vice dean of the Office of Human Research, Taipei Medical University. Dr. Liu received his M.D. degree from the School of Medicine, Taipei Medical University in 1999 and the Ph.D. degree from the School of Dentistry, Taipei Medical University in 2014.

Kwo-Liang Chen, Independent Director Nominee, will serve as a Director of PubCo following the consummation of the Business Combination. Mr. Chen has served as Deputy Director-General at Hsinchu Science Park Bureau, National Science and Technology Council of Taiwan (NSTC) from July 2024 till now. From July 2022 to July 2024, he served as Director-General at the Department of Foresight and Innovation Policies, NSTC. From September 2020 to July 2022, he served as Director-General at the Department of Foresight and Innovation Policies, Ministry of Science and Technology (MOST) of Taiwan. From January 2018 to September 2020, Mr. Chen served as Chief Secretary at the Small and Medium Enterprise Administration, Ministry of Economic Affairs of Taiwan (MOEA). Mr. Chen received his Doctor of Philosophy degree from the Department of Business Administration, National Chiao Tung University (now part of National Yang Ming Chiao Tung University) in 2004.

John C. General, Independent Director Nominee, will serve as a Director of PubCo following the consummation of the Business Combination. Mr. General serves as the Vice President of Revenue Accounting for Moody’s Corporation where he is responsible for the technical analysis of transactions and the assurance of the proper recognition and recording of transactions relating to revenue recognition. He served as an advisor to Workday and Google regarding revenue recognition for complex contract arrangements. He served as Senior Manager of Global Revenue Assurance for Avaya, responsible for the appropriate recognition of revenue under current accounting standards, and review of transactions for audit purposes from April 2013 to June 2020. He served as a manager of financial operations for Bed Bath & Beyond, Value Services Inc., responsible for the controllership and compliance reporting for the company’s gift card business for all retail concepts from July 2010 to April 2013. He served as a director in the department of SOX Implementation for Virgin Mobile, responsible for ensuring SOX compliance from July 2004 to March 2009. From September 1986 to December 2003, he served in various positions at AT&T Corp., where he last served as a Financial Director responsible for revenue assurance and billing operations. He holds a license as a Certified Public Accountant, a certificate in Senior Executive Education from Columbia University, an MBA in Finance from Rutgers University, and bachelor’s degrees in both economics and accounting from Fairleigh Dickinson University.